Merck and Moderna Weigh Next Steps in Cancer Vaccine Program

· Health · United States

At the STAT Summit, Merck and Moderna executives said the two companies still have "a lot of exploring to do" after initial success with their personalized mRNA cancer vaccine. Stephen Hoge and Dean Li described how the partners will pair Merck's Keytruda with the tailored vaccines to target tumors. The program is among the most closely watched in oncology because it combines an established checkpoint inhibitor with a vaccine designed around an individual patient's tumor mutations. The comments follow a melanoma patient's account of receiving the vaccine, which offered hope and a path forward after diagnosis. The collaboration's direction will shape expectations for personalized cancer vaccines more broadly.

Why it matters：The partnership is a bellwether for personalized mRNA cancer vaccines, and its next steps will shape how the industry views the platform.

Key points

  • Executives spoke at the STAT Summit about the program.
  • The vaccine is paired with Merck's Keytruda to target tumors.
  • A melanoma patient described receiving the vaccine.

Sources (original reporting)

More stories from this day